CA2982508A1 - Means for diagnosing, predicting or monitoring pneumocystis pneumonia - Google Patents
Means for diagnosing, predicting or monitoring pneumocystis pneumonia Download PDFInfo
- Publication number
- CA2982508A1 CA2982508A1 CA2982508A CA2982508A CA2982508A1 CA 2982508 A1 CA2982508 A1 CA 2982508A1 CA 2982508 A CA2982508 A CA 2982508A CA 2982508 A CA2982508 A CA 2982508A CA 2982508 A1 CA2982508 A1 CA 2982508A1
- Authority
- CA
- Canada
- Prior art keywords
- jirovecii
- gene
- seq
- mitochondrial
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000000317 pneumocystosis Diseases 0.000 title claims abstract description 227
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 title claims abstract description 223
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 title claims abstract description 223
- 238000012544 monitoring process Methods 0.000 title abstract description 6
- 241000142787 Pneumocystis jirovecii Species 0.000 claims abstract description 446
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 287
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 238
- 108020005196 Mitochondrial DNA Proteins 0.000 claims abstract description 221
- 238000011002 quantification Methods 0.000 claims abstract description 107
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 101150001086 COB gene Proteins 0.000 claims abstract description 43
- 101150053771 MT-CYB gene Proteins 0.000 claims abstract description 43
- 101150006264 ctb-1 gene Proteins 0.000 claims abstract description 43
- 229940079593 drug Drugs 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 43
- 101150088166 mt:Cyt-b gene Proteins 0.000 claims abstract description 43
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 30
- 108020004418 ribosomal RNA Proteins 0.000 claims abstract description 29
- 101800002927 Small subunit Proteins 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 321
- 239000002773 nucleotide Substances 0.000 claims description 193
- 239000002299 complementary DNA Substances 0.000 claims description 163
- 230000000295 complement effect Effects 0.000 claims description 137
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 63
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 59
- 108091093088 Amplicon Proteins 0.000 claims description 47
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 30
- 102100034343 Integrase Human genes 0.000 claims description 26
- 238000000746 purification Methods 0.000 claims description 19
- 238000010839 reverse transcription Methods 0.000 claims description 18
- 238000012408 PCR amplification Methods 0.000 claims description 16
- 238000002123 RNA extraction Methods 0.000 claims description 16
- 230000003321 amplification Effects 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 238000003753 real-time PCR Methods 0.000 claims description 15
- 239000013060 biological fluid Substances 0.000 claims description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 239000000969 carrier Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 210000002345 respiratory system Anatomy 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 238000004364 calculation method Methods 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims description 2
- 102100025287 Cytochrome b Human genes 0.000 claims 1
- 101000858267 Homo sapiens Cytochrome b Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 34
- 125000003729 nucleotide group Chemical group 0.000 description 185
- 108020004414 DNA Proteins 0.000 description 87
- 238000009396 hybridization Methods 0.000 description 76
- 238000011529 RT qPCR Methods 0.000 description 29
- 239000012634 fragment Substances 0.000 description 28
- 108090000704 Tubulin Proteins 0.000 description 22
- 102000004243 Tubulin Human genes 0.000 description 21
- 208000036815 beta tubulin Diseases 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 20
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 17
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 17
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 238000010240 RT-PCR analysis Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 101150093272 ATP9 gene Proteins 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 101100324954 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) oli gene Proteins 0.000 description 10
- 101150096101 OLI1 gene Proteins 0.000 description 10
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 10
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 10
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 9
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 8
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 8
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 8
- 206010061598 Immunodeficiency Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 229940047766 co-trimoxazole Drugs 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 6
- 108060002716 Exonuclease Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000013165 exonuclease Human genes 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 101000604411 Homo sapiens NADH-ubiquinone oxidoreductase chain 1 Proteins 0.000 description 4
- 101000891654 Homo sapiens TATA-box-binding protein Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102100038625 NADH-ubiquinone oxidoreductase chain 1 Human genes 0.000 description 4
- 238000002944 PCR assay Methods 0.000 description 4
- 241000233870 Pneumocystis Species 0.000 description 4
- 108020004518 RNA Probes Proteins 0.000 description 4
- 239000003391 RNA probe Substances 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 241000239226 Scorpiones Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960000860 dapsone Drugs 0.000 description 4
- 102000045334 human TBP Human genes 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229960000611 pyrimethamine Drugs 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710084021 Large envelope protein Proteins 0.000 description 3
- 229940123317 Sulfonamide antibiotic Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 108010020326 Caspofungin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100031242 Deoxyhypusine synthase Human genes 0.000 description 2
- 108010049047 Echinocandins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150031823 HSP70 gene Proteins 0.000 description 2
- 101000844963 Homo sapiens Deoxyhypusine synthase Proteins 0.000 description 2
- 108091023242 Internal transcribed spacer Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 238000013381 RNA quantification Methods 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003409 anti-rejection Effects 0.000 description 2
- 229960003159 atovaquone Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 2
- 229960003034 caspofungin Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 229960005179 primaquine Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- -1 CYTB Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102100041024 Cytochrome c oxidase assembly protein COX11, mitochondrial Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000748842 Homo sapiens Cytochrome c oxidase assembly protein COX11, mitochondrial Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 210000002383 alveolar type I cell Anatomy 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004993 binary fission Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- YJHDFAAFYNRKQE-YHPRVSEPSA-L disodium;5-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[(e)-2-[4-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].N=1C(NC=2C=C(C(\C=C\C=3C(=CC(NC=4N=C(N=C(NC=5C=CC=CC=5)N=4)N(CCO)CCO)=CC=3)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)=NC(N(CCO)CCO)=NC=1NC1=CC=CC=C1 YJHDFAAFYNRKQE-YHPRVSEPSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 101150036739 nad11 gene Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305562 | 2015-04-15 | ||
| EP15305562.9 | 2015-04-15 | ||
| PCT/EP2016/058355 WO2016166287A1 (en) | 2015-04-15 | 2016-04-15 | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2982508A1 true CA2982508A1 (en) | 2016-10-20 |
Family
ID=52946502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2982508A Abandoned CA2982508A1 (en) | 2015-04-15 | 2016-04-15 | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11236390B2 (enExample) |
| EP (1) | EP3283643B8 (enExample) |
| JP (1) | JP7072385B2 (enExample) |
| CN (1) | CN107636172B (enExample) |
| CA (1) | CA2982508A1 (enExample) |
| DK (1) | DK3283643T3 (enExample) |
| WO (1) | WO2016166287A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60239271D1 (de) * | 2001-05-08 | 2011-04-07 | Shima Seiki Mfg | Verfahren zum herstellen strickware mit bund auf eine flachstrickmaschine |
| WO2016166287A1 (en) * | 2015-04-15 | 2016-10-20 | Institut Pasteur | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
| CN107354221A (zh) * | 2017-08-28 | 2017-11-17 | 合肥千麦医学检验所有限公司 | 耶氏肺孢子菌的pcr检测试剂盒 |
| KR102026553B1 (ko) * | 2018-01-08 | 2019-09-27 | 조선대학교산학협력단 | 다복제유전자를 이용한 쯔쯔가무시병의 진단방법 |
| CN109251992A (zh) * | 2018-09-13 | 2019-01-22 | 昆明医科大学第附属医院 | 一种检测耶氏肺孢子菌的lamp引物组合物和方法 |
| CN109346174A (zh) * | 2018-10-24 | 2019-02-15 | 南昌大学第二附属医院 | 非人类免疫性缺陷病毒感染患者pcp风险评估系统 |
| CN109666755A (zh) * | 2018-12-25 | 2019-04-23 | 北京卓诚惠生生物科技股份有限公司 | 用于检测侵袭性真菌的核酸试剂、试剂盒、系统及方法 |
| CN110408717A (zh) * | 2019-07-23 | 2019-11-05 | 四川省农业科学院生物技术核技术研究所 | 灵芝属线粒体rns基因的特异扩增引物及其应用 |
| WO2021039540A1 (ja) * | 2019-08-23 | 2021-03-04 | 富士フイルム和光純薬株式会社 | ニューモシスチス・イロベチイ検出用プライマー対、これを用いたニューモシスチス・イロベチイの検出方法及びそのための試薬キット |
| CN111424101A (zh) * | 2020-03-30 | 2020-07-17 | 广州市第八人民医院 | 一种用于定量检测耶氏肺孢子菌的试剂盒和方法 |
| CN111455094B (zh) * | 2020-06-17 | 2020-09-08 | 圣湘生物科技股份有限公司 | 检测深部感染真菌的组合物、试剂盒、用途及其方法 |
| CN113088579B (zh) * | 2021-03-16 | 2022-03-22 | 广州医科大学附属第一医院 | 一种用于定性检测耶氏肺孢子菌的试剂盒和方法 |
| ES2933149A1 (es) * | 2021-07-28 | 2023-02-01 | Fundacion Para El Fomento De La Investig Sanitaria Y Biomedica De La Comunitat Valenciana Fisabio | METODO in vitro PARA EL DIAGNOSTICO DE UNA INFECCION POR Pneumocystis jirovecii |
| CN115029471A (zh) * | 2022-05-27 | 2022-09-09 | 大连干细胞与精准医学创新研究院 | 一种基于数字pcr技术检测耶氏肺孢子菌的试剂盒及检测方法 |
| CN115820921B (zh) * | 2022-12-19 | 2024-07-05 | 领航基因科技（杭州）有限公司 | 三种肺侵袭性真菌检测的引物探针组合及其数字pcr试剂盒 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110189676A1 (en) * | 2008-10-03 | 2011-08-04 | Hall Thomas A | Compositions for use in identification of fungi |
| WO2014071946A1 (en) * | 2012-11-07 | 2014-05-15 | Statens Serum Institut | Diagnostic pcr primers enabling exhaustive detection of non-human eukaryotic ssu rdna in human clinical samples |
| WO2016166287A1 (en) * | 2015-04-15 | 2016-10-20 | Institut Pasteur | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
-
2016
- 2016-04-15 WO PCT/EP2016/058355 patent/WO2016166287A1/en not_active Ceased
- 2016-04-15 CA CA2982508A patent/CA2982508A1/en not_active Abandoned
- 2016-04-15 CN CN201680021613.0A patent/CN107636172B/zh not_active Expired - Fee Related
- 2016-04-15 DK DK16717131.3T patent/DK3283643T3/da active
- 2016-04-15 US US15/564,246 patent/US11236390B2/en active Active
- 2016-04-15 JP JP2017553984A patent/JP7072385B2/ja active Active
- 2016-04-15 EP EP16717131.3A patent/EP3283643B8/en active Active
-
2021
- 2021-12-15 US US17/552,130 patent/US20220119886A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3283643B8 (en) | 2020-06-10 |
| CN107636172A (zh) | 2018-01-26 |
| WO2016166287A1 (en) | 2016-10-20 |
| EP3283643A1 (en) | 2018-02-21 |
| DK3283643T3 (da) | 2020-05-18 |
| US11236390B2 (en) | 2022-02-01 |
| US20180127825A1 (en) | 2018-05-10 |
| EP3283643B1 (en) | 2020-04-15 |
| JP7072385B2 (ja) | 2022-05-20 |
| JP2018511339A (ja) | 2018-04-26 |
| CN107636172B (zh) | 2021-11-16 |
| US20220119886A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220119886A1 (en) | Means for diagnosing, predicting or monitoring pneumocystis pneumonia | |
| US9758828B2 (en) | Methods to detect, treat and prevent acute cellular rejection in kidney allografts | |
| JP2016005470A (ja) | マイコバクテリアによる感染の診断方法およびそのための試薬 | |
| Sanjuan-Jimenez et al. | Lessons learned with molecular methods targeting the BCSP-31 membrane protein for diagnosis of human brucellosis | |
| Shipitsyna et al. | Evaluation of polymerase chain reaction assays for the diagnosis of Trichomonas vaginalis infection in Russia | |
| Zou et al. | Value analysis of next-generation sequencing combined with Xpert in early precise diagnosis of pulmonary tuberculosis | |
| CA3124497A1 (en) | Mitochondrial dna deletions associated with endometriosis | |
| CN111455094B (zh) | 检测深部感染真菌的组合物、试剂盒、用途及其方法 | |
| Moreira et al. | Elevated transrenal DNA (cell-free urine DNA) in patients with urinary tract infection compared to healthy controls | |
| CN115803450A (zh) | 特应性皮炎的重症度的检测方法 | |
| CN111020042B (zh) | 检测a族链球菌的组合物及方法 | |
| JP7743475B2 (ja) | アトピー性皮膚炎の検出方法 | |
| WO2023021978A1 (ja) | 自己免疫疾患を検査する方法 | |
| JP2023020631A (ja) | 全身性エリテマトーデスを検査する方法 | |
| CN114480636A (zh) | 胆汁细菌作为肝门部胆管癌诊断及预后标志物的用途 | |
| JP2022025456A (ja) | 多発性硬化症を検査する方法 | |
| CN112575078A (zh) | lncRNAs作为活动性肺结核病特异性标志物的应用 | |
| WO2021039777A1 (ja) | 関節リウマチを検査する方法 | |
| JP7767500B2 (ja) | アトピー性皮膚炎の重症度の検出方法 | |
| Callado Prat | Comparison of manual and semi-automatic RNA extraction methods using two-tailed RT-qPCR for absolute quantification as part of the sepsis diagnosis research | |
| CN118516458B (zh) | 与高原头痛病相关的microRNA标志物及其应用 | |
| JP5435612B2 (ja) | リケッチア・ジャポニカ感染症の診断方法 | |
| KR20110116644A (ko) | 결핵의 진단을 위한 정보제공방법 및 이를 위한 결핵 진단용 키트 | |
| WO2019062429A1 (zh) | 分子标记物tcons_00016233、试剂盒及应用 | |
| CN118773308A (zh) | 一种筛查高原适应性的微小核酸分子生物标志物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210413 |
|
| EEER | Examination request |
Effective date: 20210413 |
|
| EEER | Examination request |
Effective date: 20210413 |
|
| EEER | Examination request |
Effective date: 20210413 |
|
| FZDE | Discontinued |
Effective date: 20230802 |